title: Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.
abstract: Studies investigating changes in gene expression in urothelial carcinoma have generally compared tumors of different stages and grades but comparisons between low-grade, noninvasive tumors and normal urothelium are needed to identify genes involved in early tumor development. We isolated the urothelium from a low-grade tumor and corresponding normal mucosa by laser capture microdissection on frozen sections. The RNA extracted was amplified to generate suppressive subtractive cDNA libraries. Random sequencing of cDNA clones identified approximately 100 unique species. Of these 83% were known genes, 15% had homology to genes with an unknown function in humans, and 2% did not show homology to any published gene sequence. Two of the known genes, the 67-kd laminin receptor (67LR) and tumor-associated trypsin inhibitor (TATI), had previously been associated with metastatic progression in many tumor types, although 67LR has not been investigated in urothelial tumors. Immunolabeling of the original tissue with antibodies against these two genes confirmed overexpression, validating our strategy: 67LR was not expressed in the normal urothelium but was present in the tumor, whereas TATI expression was confined to umbrella cells in the normal urothelium, but extended to all cell layers in the tumor. We investigated both markers further in a separate series of tumors of different stages and grades. TATI was more consistently overexpressed than 67LR in all tumor grades and stages. Levels of secreted TATI were significantly higher in urine samples from patients with tumors compared to controls. Our strategy, combining laser capture microdissection and cDNA library construction, has identified genes that may be involved in the early phases of urothelial tumor development rather than with disease progression, highlighting the importance of comparing tumor with normal rather than just tumors of different stages and grades.
authors.affiliation: Cancer Research United Kingdom Clinical Centre, St. James's University Hospital, Leeds, UK.
authors.forename: Christine P
authors.initials: CP
authors.lastname: Diggle
authors.forename: Sheena
authors.initials: S
authors.lastname: Cruickshank
authors.forename: Jonathon D
authors.initials: JD
authors.lastname: Olsburgh
authors.forename: Stephanie
authors.initials: S
authors.lastname: Pellegrin
authors.forename: Barbara
authors.initials: B
authors.lastname: Smith
authors.forename: Rosamonde E
authors.initials: RE
authors.lastname: Banks
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Selby
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Knowles
authors.forename: Jennifer
authors.initials: J
authors.lastname: Southgate
authors.forename: Patricia
authors.initials: P
authors.lastname: Harnden
mesh_terms: D002277:Carcinoma / Q000235:genetics* / Q000473:pathology; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D015723:Gene Library; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism; D053554:Keratin-20; D007834:Lasers; D017474:Receptors, Laminin / Q000235:genetics* / Q000378:metabolism; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000235:genetics* / Q000652:urine; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology; D019459:Urothelium / Q000378:metabolism* / Q000473:pathology*
chemical_list: D007381:Intermediate Filament Proteins; C507499:KRT20 protein, human; D053554:Keratin-20; D017474:Receptors, Laminin; D014359:Trypsin Inhibitor, Kazal Pancreatic